Showing 481 - 500 results of 225,927 for search '(( 5 ((step decrease) OR (we decrease)) ) OR ( 10 ((nn decrease) OR (a decrease)) ))', query time: 1.81s Refine Results
  1. 481
  2. 482

    Administration of a Toll-Like Receptor 9 Agonist Decreases the Proviral Reservoir in Virologically Suppressed HIV-Infected Patients by Anni A. Winckelmann (407551)

    Published 2013
    “…Further, increasing proportion of HIV-specific CD107a and MIP1β-expressing CD8+ T cells were strongly correlated with decreasing proviral load. …”
  3. 483
  4. 484
  5. 485

    A phenotype of increased sleepiness in a mouse model of pulmonary hypertension and right ventricular hypertrophy by Eric M. Davis (1733638)

    Published 2018
    “…After PAB, mice spent significantly more time in NREM sleep compared to the control group over a 24 hour period (53.5 ± 1.5% vs. 46.6 ± 1.4%; p < 0.01) and exhibited an inability to both cycle into REM sleep and decrease delta density across the light/sleep period. …”
  6. 486
  7. 487
  8. 488
  9. 489
  10. 490

    The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial by Ma Somsouk (283498)

    Published 2014
    “…<div><p>The anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis. …”
  11. 491
  12. 492

    Image5_Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources.TIFF by Gabriella Gálffy (177759)

    Published 2024
    “…The COVID-19 pandemic resulted in a statistically significant decrease in lung cancer incidence, especially in the 50–59 age group (both sexes).…”
  13. 493

    Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2‑Aminoquinoline Inhibitors by Maris A. Cinelli (1309419)

    Published 2017
    “…Neuronal nitric oxide synthase (nNOS) inhibition is a promising strategy to treat neurodegenerative disorders, but the development of nNOS inhibitors is often hindered by poor pharmacokinetics. We previously developed a class of membrane-permeable 2-aminoquinoline inhibitors and later rearranged the scaffold to decrease off-target binding. …”
  14. 494
  15. 495
  16. 496

    Uptake and Population-Level Impact of Expedited Partner Therapy (EPT) on <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i>: The Washington State Community-Level Randomi... by Matthew R. Golden (136790)

    Published 2015
    “…We conducted a stepped-wedge, community-level randomized trial to determine whether a public health intervention promoting EPT could increase its use and decrease chlamydia test positivity and gonorrhea incidence in women.…”
  17. 497

    Image4_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  18. 498

    Image2_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  19. 499

    Image6_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  20. 500

    Image1_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”